Funding Support and Author Disclosures Dr Smolderen has received unrestricted research grant funding from Johnson and Johnson, Shockwave, and Merck; and has served as a consultant for Abbott, Cook Medical, Optum, Happify, and Tegus. Dr Mena-Hurtado has received unrestricted research grant funding from Shockwave; and has served as a consultant for Abbott, Cook Medical, and Optum. Dr Fucito has received paid consultation for serving on an advisory board for Ibrium Therapeutics, LLC. Dr Bonaca has equity interests/stock options in Pfizer, Medtronic, and Vertex Pharmaceuticals; has performed research for and/or received research grants from Amgen, Bayer, Arca Biopharma, Novo Nordisk, Merck and Co Inc, Wraser, AstraZeneca Pharmaceuticals, Better Therapeutics, Arca, Abbott Laboratories, Agios Pharmaceuticals, Alexion Pharma, Angionetics, Atentiv, Audentes, Bristol Myers Squibb Company, Cardiol Therapeutics, Cellresearch, Cook Regentec, CSL Behring, Eidos Therapeutics, Esperion, Everlywell, Faraday Pharmaceuticals, Fortress Biotech, Heartflow, Insmed, Kowa Research, EP Trading Company, Lexicon, Pfizer, Alnylam, Array, PPD Development, Prothena Biosciences, Regeneron, University of Colorado, Moderna, Regio Biosciences, Sanifit, Sanofi-Aventis, Stealth Biotherapeutics, Brigham and Women's Hospital, Worldwide Clinical Trials, Yale Cardiovascular Research Group, Phasebio, and Janssen Pharmaceuticals; and has received other financial benefits from the American Heart Association, Anthos Therapeutics, Cambrian Biopharma, EPG Communications, Epizon Pharma, National Institutes of Health, Novartis Corporation, St Luke's Hospital of Kansas City, Silence Therapeutics, Thrombosis Research Institute, University of Pittsburgh, and Varmx. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.